The Impact of Disease Activity on Hematological Parameters among Rheumatoid Arthritis Patients: A Cross-Sectional Analysis
DOI:
https://doi.org/10.32792/utq/utjsci/v12i2.1434Abstract
Received: 2025-07-29
Revised: 2025-08-14
Accepted: 2025-08-23
References
[1] S. Berardi, A. Corrado, N. Maruotti, D. Cici, and F. Cantatore, “Osteoblast role in the pathogenesis of rheumatoid arthritis,” Molecular Biology Reports, 2021, doi: 10.1007/s11033-021-06288-y.
[2] M. Anton, A. Cardoneanu, A. Burlui, I. Mihai, P. Richter, I. Bratoiu, L. Macovei, and E. Rezu, “The lung in rheumatoid arthritis—friend or enemy,” International Journal of Molecular Sciences, vol. 25, no. 12, Art no. 6460, 2024, doi: 10.3390/ijms25126460.
[3] H. Almoallim, J. A. Saleh, H. Badsha, H. Ahmed, S. Habjoka, J. Menassa, and A. El-Garf, “A review of the prevalence and unmet needs in the management of rheumatoid arthritis in africa and the middle east,” Rheumatology and Therapy, 2020, doi: 10.1007/s40744-020-00252.
[4] M. Zen, L. Salmaso, C. B. Amidei, A. Giollo, U. Fedeli, S. Bellio, F. Arru, I. Gennaio, M. Saia, and A. Doria, “Ab1628the incidence and prevalence of rheumatoid arthritis in italy in the last decade,” Annals of the Rheumatic Diseases, 2023, doi: 10.1136/annrheumdis-2023-eular.1432.
[5] L. Silva-Fernández, C. Macía-Villa, D. Seoane-Mato, R. Cortés-Verdú, A. Romero-Pérez, V. Quevedo-Vila, D. Fábregas-Canales, F. Antón-Pagés, G. Añez, A. Brandy, C. Martínez-Dubois, P. Sánchez-Piedra, C. Sánchez-Piedra, F. Díaz-González, and S. Bustabad-Reyes, “The prevalence of rheumatoid arthritis in spain,” Scientific Reports, 2020, doi: 10.1038/s41598-020-76511-6.
[6] M. Jahid, K. U. Khan, Rehan-Ul-Haq, and R. S. Ahmed, “Overview of rheumatoid arthritis and scientific understanding of the disease,” Mediterranean Journal of Rheumatology, 2023, doi: 10.31138/mjr.20230801.oo.
[7] N. Lapkina, A. Baranov, N. Levshin, N. Abatova, A. Avdeeva, E. Leontieva, A. Artyuhov, and E. Nasonov, “Pos0668the efficacy of tofacitinib on clinical dynamic and concentration of cytokines in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, 2022, doi: 10.1136/annrheumdis-2022-eular.354.
[8] N. Kondo, T. Kuroda, and D. Kobayashi, “Cytokine networks in the pathogenesis of rheumatoid arthritis,” International Journal of Molecular Sciences, vol. 22, no. 20, Art no. 10922, 2021, doi: 10.3390/ijms222010922.
[9] H. Yap, S. Tee, M. M. Wong, S. Chow, S. Peh, and S. Teow, “Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and,” Cells, vol. 7, no. 10, Art no. 161, 2018, doi: 10.3390/cells7100161.
[10] M. Taha, O. Shaker, E. Abdelsalam, and N. Taha, “Serum a proliferation-inducing ligand and microrna-223 are associated with rheumatoid arthritis: diagnostic and prognostic implications,” Molecular Medicine, 2020, doi: 10.1186/s10020-020-00199-7.
[11] Q. Guo, Y. Wang, D. Xu, J. Nossent, N. Pavlos, and J. Xu, “Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies,” Bone Research, 2018, doi: 10.1038/s41413-018-0016-9.
[12] Y. Ma, H. Chen, W. Lv, S. Wei, Y. Zou, R. Li, J. Wang, W. She, L. Yuan, J. Tao, X. Guo, S. Bi, H. Tian, Y. Ma, H. Sun, C. Sun, J. Xu, Y. Dong, J. Kang, and Y. Jiang, “Global, regional and national burden of rheumatoid arthritis from 1990 to 2021, with projections of incidence to 2050: a systematic and comprehensive analysis of the global burden of disease study 2021,” Biomarker Research, 2025, doi: 10.1186/s40364-025-00760-8.
[13] L. M. Alm, D. L. Fountain, K. K. Cadwell, A. M. Madrigal, G. Gallo, and M. Poorafshar, “The performance of anti-cyclic citrullinated peptide assays in diagnosing rheumatoid arthritis: a systematic review and meta-analysis,” Clin Exp Rheumatol, vol. 36, pp. 144-152, 2018.
[14] M. A. M. van Delft and T. W. J. Huizinga, “An overview of autoantibodies in rheumatoid arthritis,” J Autoimmun, vol. 110, Art no. 102392, 2020, doi: 10.1016/j.jaut.2019.102392.
[15] T. Webb, G. Lakos, A. Swart, et al., “Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies,” Clin Chim Acta, vol. 437, pp. 161-167, 2014.
[16] E. D. Gahli and H. Q. Mohammed, “Evaluation of demographic, serological and hematological data features in patients diagnosed with rheumatoid arthritis in Wasit Province,” Journal of Basrah Researches (Sciences), vol. 50, no. 2, pp. 204-216, 2024, doi: 10.56714/bjrs.50.2.17.
[17] R. M. Khadim and F. S. Al-Fartusie, “Evaluation of liver function and lipid profiles in Iraqi patients with rheumatoid arthritis,” Journal of Physics: Conference Series, vol. 1853, no. 1, Art no. 012040, 2021, doi: 10.1088/1742-6596/1853/1/012040.
[18] S. A. Khalaf, E. A. Muhsin, H. K. Ali, and W. Y. Hasan, “Evaluation of the changes in some hematological and immunological parameters in patients with rheumatoid arthritis,” Osol Journal of Medical Sciences, vol. 2024, no. 02, pp. 41-46, 2024, doi: 10.69946/ojms/2024.02.02.05.
[19] N. A. Salman, “Assessment the role of erythrocyte sedimentation rate and C-reactive protein tests for prediction of rheumatoid arthritis activity in Misan Province,” Al-Manara College for Medical Sciences, 2024. [Online]. Available: naderabed@uomanara.edu.iq.
[20] A. K. Zgair and R. H. Ahmad, “Immunological and biological manifestation of rheumatoid arthritis patient in Iraq,” Indian Journal of Forensic Medicine & Toxicology, vol. 15, no. 4, p. 1344, 2021.
[21] Z. J. Diwan and W. A. Al-Marsomy, “Evaluation of several hematologic and serological parameters in rheumatoid arthritis patients,” Journal of the Faculty of Science for Women, University of Baghdad, vol. 37, no. 2, 2024, doi: 10.30526/37.2.3451.
[22] S. A. Salman and R. M. Kh. Al-Jumaily, “Immunological role of IL-3, IL-5 and some inflammation markers in a sample of Iraqi patients with rheumatoid arthritis,” Journal of Education for Pure Science, vol. 37, no. 4, Art no. 3493, 2024, doi: 10.30526/37.4.3493.
[23] M. H. Sulaiman, R. M. Rashied, and L. A. Mahmood, “Evaluation of the lipid profile and its correlation to inflammatory markers in a sample of rheumatoid arthritis patients in Iraq,” Journal of University of Anbar for Pure Science, vol. 17, no. 1, pp. 33-41, 2023.
[24] I. A. Chiad, H. S. Yossef, M. A. Al-Saidi, and M. A. Abbas, “Evaluation of some immunological markers in the rheumatoid arthritis patients,” Iraqi Journal of Science, vol. 56, no. 3C, pp. 2488-2493, 2015. [Online]. Available: https://ijs.uobaghdad.edu.iq/index.php/eijs/article/view/1485.
[25] M. A. Al-Karkhi, A. R. Al-Derzi, S. M. H. Mohammed Zeiny, N. A. Jassim, B. M. Mahdi, and M. M. Al-Ani, “Correlation between anti-infliximab and anti-CCP antibodies development in patients with rheumatoid arthritis treated with infliximab in Baghdad Teaching Hospital,” IOSR Journal of Dental and Medical Sciences, vol. 14, no. 11, pp. 95-100, 2015. [Online]. Available: http://www.iosrjournals.org/iosr-jdms/papers/Vol14-issue11/Version-4/P01411495100.pdf.
[26] D. A. K. Ali, M. M. Al-Ani, N. A. L. Al-Ani, and A. Al-Rubaee, “Assessment of the correlation between disease activity and serum biomarker Anti-MCV and IL6 in Iraqi patients with rheumatoid arthritis,” Journal of the Faculty of Medicine Baghdad, vol. 66, no. 1, Art no. e2359, 2024, doi: 10.32007/jfacmedbaghdad.6632359.
[27] S. A. Shahrazad, W. Y. Hasan, and H. M. Kareem, “Serological and inflammatory markers in female patients with rheumatoid arthritis in Baghdad,” Baghdad Science Journal, vol. 20, no. 3, p. 455461, 2025. [Online]. Available: https://iasj.rdd.edu.iq/viewarticle.html?id=14ae4c3d94511124b24816665f83dc89.
[28] Y. H. Lee and S.-C. Bae, “Associations between circulating IL-17 levels and rheumatoid arthritis and between IL-17 gene polymorphisms and disease susceptibility: A meta-analysis,” Postgraduate Medical Journal, vol. 93, no. 1102, pp. 465-471, 2017, doi: 10.1136/postgradmedj-2016-134637.
[29] M. Robert and P. Miossec, “IL-17 in rheumatoid arthritis and precision medicine: From synovitis expression to circulating bioactive levels,” Frontiers in Medicine, vol. 5, Art no. 364, 2019, doi: 10.3389/fmed.2018.00364.
[30] P. Bhattacharya, S. F. Alam, A. Singh, and S. Ghosh, “Interleukin-17F gene polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis,” Scientific Reports, vol. 13, no. 1, Art no. 1432, 2023, doi: 10.1038/s41598-023-46888-1.
Downloads
Published
License
Copyright (c) 2025 University of Thi-Qar Journal of Science

This work is licensed under a Creative Commons Attribution 4.0 International License.











